OncoMatch/Clinical Trials/NCT07501156
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Is NCT07501156 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies H3K27M-EIEs for diffuse midline glioma or diffuse intrinsic pontine glioma.
Treatment: H3K27M-EIEs — The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine glioma. Another goal of the study is to learn more about the function of the anti-H3K27M EIE cells and their persistency in patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Intrinsic Pontine Glioma
Biomarker criteria
Required: H3-3A K27M
confirmed H3K27M mutation
Demographics
Prior therapy
Must have received: standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ) (temozolomide)
Patients have received standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ)
Cannot have received: gliadel implantation
Exception: within 4 weeks before study start
A prior history of gliadel implantation 4 weeks before this study start
Cannot have received: antibody based therapies
Exception: currently receiving
currently receiving antibody based therapies
Lab requirements
Blood counts
absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000 /mm^3; Peripheral blood absolute lymphocyte count must be above 0.8×10^9/L
Kidney function
creatinine < 1.5×ULN
Liver function
Bilirubin < 1.5×ULN; ALT or AST < 2.5×ULN
Cardiac function
Satisfactory heart functions
Satisfactory bone marrow, liver and kidney functions as defined by the following: absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000 /mm^3; Bilirubin < 1.5×ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5×ULN; creatinine < 1.5×ULN; Peripheral blood absolute lymphocyte count must be above 0.8×10^9/L; Satisfactory heart functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07501156 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gliadel implantation, antibody based therapies disqualifies patients from enrollment.
Does this trial require H3-3A?
Yes, H3-3A K27M is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify